Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

David Wild

David’s reporting since 2001 has focused on the clinical aspects of medicine, particularly in the American health system. He’s covered everything from novel drugs for inflammatory bowel disease (think back to the advent of biologics!) to protocols for fine-tuning use of anticoagulants post-operatively, and from the fallout of medication compounding disasters to regulatory concerns about the 340B Drug Pricing Program. He has covered dozens of medical conferences and profiled numerous clinicians and institutions. David is a native of Israel and lives in Toronto, Canada. His hobbies include playing music, gardening, camping and spending time with his wife, son and mini-Bernedoodle, Moishe.

Latest From David Wild

Twist's Unconventional Approach, Adding Value One Rung At A Time

Building a narrow set of products and services that provide reliable and consistent revenue is a perfectly sound business strategy and one that sustains many biotech companies. But for the hungrier, like Twist Bioscience, Inc., a strategy of ongoing disruption and evolution has been more appealing and indeed is generating significant growth. Emily Leproust, Twist’s CEO, spoke with In Vivo about what it means to follow a value-added business strategy.

Business Strategies Commercial

Regulators Keep Rare Diseases Open For Business

The cost of rare diseases to patients and society at large is 10 times higher than for many of the biggest mass market diseases combined. With 95% of rare diseases lacking a treatment or cure, there is an economic imperative for policymakers to keep encouraging pharmaceutical companies to develop more orphan drug treatments. In Vivo looks at the US and EU regulatory impetus to keep rare diseases open for innovation. 

Rare Diseases FDA

Overcoming Rare Disease Trial Recruitment Challenges

Rare disease treatments have been increasingly attractive targets for investment, but clinical trials of these agents are laden with unique challenges, not least of which is that there are by definition small and possibly disparately located patient populations. However, by cultivating relationships with patient organizations and carefully designing studies, companies in the rare disease space are proving they can overcome logistical hurdles. 

Clinical Trials Companies

Tackling The Problem Of Fake Medicines

Despite a raft of measures to prevent substandard or falsified (SF) medicines from reaching individuals, these medicines proliferated with the growth of e-commerce during the COVID-19 pandemic. The problem requires multistakeholder counter efforts, and for providers and patients to change their behaviors.

Distribution Drug Safety

Accenture: Acquisition Of Early-Stage Assets, Bio-Platforms Key To Accelerated Growth

Acquisitions of early-stage assets, biotech platforms and capabilities like AI are the way to faster growth for pharma companies, as Accenture’s Petra Jantzer told In Vivo. However, changing the focus of M&A away from conventional late-stage assets requires significant shifts in corporate and R&D culture.

Business Strategies Deals

Bucking Convention, AavantiBio Co-Founder Marries Clinical Physical Therapy with Gene Therapy Research

There is no single road to leadership in biotech, as In Vivo Rising leader Manuela Corti demonstrates. The physical therapist shares her passion for treating neuromuscular disorders, the urgency of commercializing gene therapy treatment for these diseases, and the value of infusing the work environment with some fun.

United States Rising Leaders
See All
UsernamePublicRestriction

Register